Longitudinal Immune-phenotyping of HCC Following MK-3475

NCT04224480 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

National Cancer Centre, Singapore

Collaborators

[object Object]
[object Object]